Adjuvant anti-HER2 monoclonal antibody therapy - Ready for breast cancer?

E. A. Perez

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

A large number of patients diagnosed with early breast cancer worldwide derive improvements in disease-free survival (DFS) and overall survival with the use of available systemic adjuvant therapies. However, there is still much work to be done. Further improvements in clinical outcomes will significantly depend on the identification of prognostic and therapeutic targets through molecular medicine. The paradigm for these biological determinants is exemplified by HER2 and the chimeric humanized antibody that targets the extracellular domain of the HER2 gene product (HER2) in advanced breast cancer, trastuzumab. In clinical trials, this anti-HER2 monoclonal antibody has been demonstrated to be active as a single agent and has been shown to improve survival when it is added to two standard chemotherapy regimens in patients with metastatic breast cancer. Thus, it is logical that randomized phase III clinical trials have been designed and initiated to determine whether trastuzumab improves the efficacy of chemohormonal adjuvant treatment for patients at high risk of tumuor relapse based on amplification of the HER2 gene and/or HER2 protein overexpression.

Original languageEnglish (US)
Pages (from-to)161-163
Number of pages3
JournalBreast
Volume10
Issue numberSUPPL. 3
StatePublished - 2001

Fingerprint

erbB-2 Genes
Monoclonal Antibodies
Breast Neoplasms
Molecular Medicine
Antibodies, Monoclonal, Humanized
Phase III Clinical Trials
Survival
Disease-Free Survival
Therapeutics
Randomized Controlled Trials
Clinical Trials
Recurrence
Drug Therapy
Proteins
Trastuzumab

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Adjuvant anti-HER2 monoclonal antibody therapy - Ready for breast cancer? / Perez, E. A.

In: Breast, Vol. 10, No. SUPPL. 3, 2001, p. 161-163.

Research output: Contribution to journalArticle

Perez, EA 2001, 'Adjuvant anti-HER2 monoclonal antibody therapy - Ready for breast cancer?', Breast, vol. 10, no. SUPPL. 3, pp. 161-163.
Perez, E. A. / Adjuvant anti-HER2 monoclonal antibody therapy - Ready for breast cancer?. In: Breast. 2001 ; Vol. 10, No. SUPPL. 3. pp. 161-163.
@article{8020e987f2e54c4bb7fd72e70865948b,
title = "Adjuvant anti-HER2 monoclonal antibody therapy - Ready for breast cancer?",
abstract = "A large number of patients diagnosed with early breast cancer worldwide derive improvements in disease-free survival (DFS) and overall survival with the use of available systemic adjuvant therapies. However, there is still much work to be done. Further improvements in clinical outcomes will significantly depend on the identification of prognostic and therapeutic targets through molecular medicine. The paradigm for these biological determinants is exemplified by HER2 and the chimeric humanized antibody that targets the extracellular domain of the HER2 gene product (HER2) in advanced breast cancer, trastuzumab. In clinical trials, this anti-HER2 monoclonal antibody has been demonstrated to be active as a single agent and has been shown to improve survival when it is added to two standard chemotherapy regimens in patients with metastatic breast cancer. Thus, it is logical that randomized phase III clinical trials have been designed and initiated to determine whether trastuzumab improves the efficacy of chemohormonal adjuvant treatment for patients at high risk of tumuor relapse based on amplification of the HER2 gene and/or HER2 protein overexpression.",
author = "Perez, {E. A.}",
year = "2001",
language = "English (US)",
volume = "10",
pages = "161--163",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Adjuvant anti-HER2 monoclonal antibody therapy - Ready for breast cancer?

AU - Perez, E. A.

PY - 2001

Y1 - 2001

N2 - A large number of patients diagnosed with early breast cancer worldwide derive improvements in disease-free survival (DFS) and overall survival with the use of available systemic adjuvant therapies. However, there is still much work to be done. Further improvements in clinical outcomes will significantly depend on the identification of prognostic and therapeutic targets through molecular medicine. The paradigm for these biological determinants is exemplified by HER2 and the chimeric humanized antibody that targets the extracellular domain of the HER2 gene product (HER2) in advanced breast cancer, trastuzumab. In clinical trials, this anti-HER2 monoclonal antibody has been demonstrated to be active as a single agent and has been shown to improve survival when it is added to two standard chemotherapy regimens in patients with metastatic breast cancer. Thus, it is logical that randomized phase III clinical trials have been designed and initiated to determine whether trastuzumab improves the efficacy of chemohormonal adjuvant treatment for patients at high risk of tumuor relapse based on amplification of the HER2 gene and/or HER2 protein overexpression.

AB - A large number of patients diagnosed with early breast cancer worldwide derive improvements in disease-free survival (DFS) and overall survival with the use of available systemic adjuvant therapies. However, there is still much work to be done. Further improvements in clinical outcomes will significantly depend on the identification of prognostic and therapeutic targets through molecular medicine. The paradigm for these biological determinants is exemplified by HER2 and the chimeric humanized antibody that targets the extracellular domain of the HER2 gene product (HER2) in advanced breast cancer, trastuzumab. In clinical trials, this anti-HER2 monoclonal antibody has been demonstrated to be active as a single agent and has been shown to improve survival when it is added to two standard chemotherapy regimens in patients with metastatic breast cancer. Thus, it is logical that randomized phase III clinical trials have been designed and initiated to determine whether trastuzumab improves the efficacy of chemohormonal adjuvant treatment for patients at high risk of tumuor relapse based on amplification of the HER2 gene and/or HER2 protein overexpression.

UR - http://www.scopus.com/inward/record.url?scp=0034915442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034915442&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 161

EP - 163

JO - Breast

JF - Breast

SN - 0960-9776

IS - SUPPL. 3

ER -